Pacira Pharmaceuticals (PCRX) PT Lowered to $82 at Needham & Company, Following Earnings
Tweet
Share
E-mail
Get Alerts PCRX Hot Sheet
Price: $24.48 --0%
Rating Summary:
12 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 8 | New: 23
Rating Summary:
12 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 8 | New: 23
Join SI Premium – FREE
Needham & Company analyst Serge Belanger lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $82.00 (from $85.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Upgrades Dynatrace Inc. (DT) to Buy
- Kalshi leads prediction market with 76% share in NFL week 1
- Needham Reiterates Buy Rating on DraftKings Inc. (DKNG) Post Management Meet
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Needham & Company, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
